Tafamidis meglumine, a transthyretin (TTR) stabilizer, is effective in delaying the progression of neuropathy in TTR amyloidosis with Val30Met mutations. However, its efficacy in TTR amyloid cardiomyopathy is not fully elucidated. Herein, we report a 73-year-old Japanese man with a diagnosis of TTR amyloid cardiomyopathy with Val30Met mutation treated with tafamidis. To evaluate treatment response, cardiac magnetic resonance imaging was performed before and after 12 months of tafamidis treatment. Native T1, extracellular volume, and left ventricular mass showed no obvious worsening, and findings of other diagnostic studies also supported the efficacy of tafamidis to delay the progression of amyloid cardiomyopathy. Our case suggests that serial native T1 and extracellular volume may be novel non-invasive imaging methods to monitor the treatment response to TTR stabilizers in cardiac amyloidosis and also that tafamidis may be effective in suppressing cardiac progression in TTR amyloid cardiomyopathy with Val30Met mutation.
Introduction
It has been demonstrated that tafamidis meglumine (Vyndaqel®; Pfizer Inc., New York, NY, USA), a transthyretin (TTR) stabilizer, is effective against peripheral neurological impairment in TTR amyloidosis with Val30Met mutations. 1, 2 However, its efficacy in TTR amyloid cardiomyopathy with Val30Met mutations is not fully elucidated. Cardiac magnetic resonance (CMR) imaging has emerged as an imaging technique in cardiac amyloidosis that provides detailed information about the presence, location, and distribution of hypertrophy, as well as visualization and measurement of cardiac amyloid infiltration. Both myocardial native T1 and extracellular volume (ECV) using CMR imaging have been validated as surrogate markers of infiltration and have been shown to correlate with disease burden with high diagnostic and prognostic value in TTR cardiac amyloidosis. 3 Herein, we report a case of TTR amyloidosis with Val30Met mutation, with serial native T1 and ECV assessments to evaluate the treatment response to tafamidis.
Case report
A 73-year-old Japanese man was transferred to our hospital with dyspnoea. He had no medical or family history of note. Blood pressure was 140/75 mmHg, heart rate 137 beats/min, and respiratory rate 24/min with oxygen saturation of 92% C A S E R E P O R T Figure 1A-C) . Genetic analysis revealed Val30Met mutation (GTG → ATG), Monitoring treatment response to tafamidis by CMR 233 indicating a diagnosis of hereditary TTR amyloidosis. The patient showed vitreous opacities and chronic glaucoma, suggesting ocular amyloidosis, without peripheral/autonomic neuropathy or carpal tunnel syndrome. The patient was started on tafamidis 20 mg per day for prophylaxis against progression of neuropathy.
To evaluate the efficacy of tafamidis treatment on cardiac lesions, the patient underwent 3 tesla CMR evaluations before and after 12 months of tafamidis treatment. CMR imaging before tafamidis treatment showed diffuse LV hypertrophy ( Figure 1D-F) and diffuse myocardial late gadolinium enhancement ( Figure 1G-I) , which showed no obvious progression at follow-up (LV mass by CMR: 115.0 g before and 111.3 g at 12 months). As shown in Figure 2 , prolonged native T1 time (1387 ms) and increased ECV (42.0%) were observed before tafamidis treatment, and no obvious worsening was found at 12 months follow-up (native T1 time of 1356 ms and ECV of 40.4%). Troponin T and B-type natriuretic peptide levels were unchanged at 0.016 ng/mL and 271.5 pg/mL, respectively, after 12 months of tafamidis. Echocardiography showed no significant progression in LV morphological features (interventricular septum/posterior wall thickness of 12/12 mm, LV end-diastolic/end-systolic dimension of 43/25 mm, and LV mass of 184.1 g), with LV ejection fraction of 60%, as well as no obvious changes in LA size, diastolic function, or RV systolic function (LA diameter of Figure 3 , which also showed no obvious change in QRS width or inverted T waves.
Discussion
We report a case of TTR amyloid cardiomyopathy with Val30Met mutation, with serial native T1 and ECV evaluation using CMR imaging to evaluate the treatment response to tafamidis on cardiac lesions. Native T1 and ECV showed no significant worsening after 12 months of tafamidis treatment, suggesting that tafamidis may have suppressed cardiac progression. We also found no significant progression of LV mass at 12 months (2% increase by echocardiography and 3% decrease by CMR imaging), in contrast to the rapid progression reported in TTR amyloid cardiomyopathy (LV mass increase in 12 months: 9% by CMR imaging and 22% by echocardiography) and changes in LV morphological features associated with a poor prognosis. 4, 5 Findings of other diagnostic studies, including no obvious change in LV diastolic function, 6 also supported the efficacy of tafamidis to delay the progression of amyloid cardiomyopathy. To the best of our knowledge, our case is the first published report of a serial evaluation of tafamidis treatment using native T1 and ECV in TTR amyloid cardiomyopathy.
The efficacy of tafamidis treatment in TTR amyloid cardiomyopathy is not fully elucidated. In TTR amyloidosis with non-Val30Met mutations, recent reports including the Phase 3 ATTR-ACT Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial) have reported the potential of TTR stabilizers (diflunisal or tafamidis) to slow cardiac progression and improve survival [7] [8] [9] [10] [11] ; however, the efficacy of tafamidis in TTR amyloid cardiomyopathy with Val30Met mutation has not been elucidated. Our case suggests that tafamidis may be effective in suppressing cardiac progression in TTR amyloid cardiomyopathy with Val30Met mutation, based on our serial CMR evaluations. Further studies are required to evaluate whether the efficacy of tafamidis on the myocardial substrate differs between early-onset and late-onset Val30Met cases [12] [13] [14] or among TTR amyloid cardiomyopathies with other mutations. Monitoring treatment response to tafamidis by CMR 235
In conclusion, serial native T1 and ECV evaluation using CMR imaging may be novel non-invasive imaging methods to monitor the treatment response to TTR stabilizers in cardiac amyloidosis. Our case also suggests that tafamidis may suppress cardiac progression in TTR amyloid cardiomyopathy with Val30Met mutations.
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